<DOC>
	<DOCNO>NCT00448136</DOCNO>
	<brief_summary>This 2 arm study ass efficacy safety two systemic treatment include Avastin patient previously-untreated progressive locally advanced/metastatic well-differentiated digestive endocrine tumor . Patients duodeno-pancreatic tumor ( arm 1 ) treat 5FU/streptozotocin iv ( 5FU 400mg/m2/d D1 D5 ; streptozotocin 500mg/m2/d/iv D1 D5 ; D1=D42 ) every 6 week , plus Avastin 7.5mg/kg iv every 3 week . Patients gastrointestinal tract tumor ( arm 2 ) treat Xeloda 1000mg/m2 po bid D1 D14 plus Avastin 7.5mg/kg iv D1=D21 every 3 week . The patient treat chemotherapy minimum 6 month , unless tumor progression and/or unacceptable toxicity . The anticipated time study treatment disease progression unacceptable toxicity , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Chemotherapy Patients With Endocrine Tumors Gastrointestinal Tract .</brief_title>
	<detailed_description />
	<mesh_term>Endocrine Gland Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Streptozocin</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; welldifferentiated gastrointestinal tract endocrine tumor , duodenopancreatic endocrine tumor ; previous anticancer therapy , surgery ; progressive metastatic disease ; &gt; =1 measurable lesion . abnormal cardiac function , history ischemic heart disease past 6 month and/or abnormal 12 lead ECG ; patient know bleed disorder ; unstable systemic disease ; chronic daily treatment highdose aspirin , NSAIDs corticosteroid ; previous history malignancy ( successfully treat basal squamous cell cancer skin , and/or situ cancer cervix ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>